[{"id":"41c79a8f-32f5-4120-a3a7-4d561141ced0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04553133","created_at":"2021-01-18T21:46:10.057Z","updated_at":"2024-07-02T16:35:03.345Z","phase":"Phase 1/2","brief_title":"PF-07104091 as a Single Agent and in Combination Therapy","source_id_and_acronym":"NCT04553133","lead_sponsor":"Pfizer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • tegtociclib (PF-07104091)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 09/16/2020","start_date":" 09/16/2020","primary_txt":" Primary completion: 03/06/2025","primary_completion_date":" 03/06/2025","study_txt":" Completion: 03/06/2025","study_completion_date":" 03/06/2025","last_update_posted":"2024-05-16"}]